From 2022 to 2023, there was a decrease in the age-adjusted rate of drug overdose death in the United States, according to a report published in the February Health E-Stats, a publication of the National Center for Health Statistics.
Matthew F. Garnett, M.P.H., and Arialdi M. Miniño, M.P.H., from the National Center for Health Statistics in Hyattsville, Maryland, describe changes in drug overdose mortality by selected drug type and state from 2022 to 2023.
The researchers found that from 2022 to 2023 the age-adjusted rate of drug overdose deaths in the United States decreased 4.0 percent (32.6 to 31.3 deaths per 100,000 standard population). West Virginia and the District of Columbia were the jurisdictions with the highest rates in 2023 (81.9 and 60.7, respectively), while Nebraska and South Dakota were the states with the lowest rates (9.0 and 11.2, respectively).
Age-adjusted rates of drug overdose deaths decreased in 20 states, did not change significantly in 25 states, and increased in six states (Alabama, Alaska, California, Nevada, Oregon, and Washington).
Nationally, the age-adjusted rate of drug overdose deaths decreased between 2022 and 2023 for deaths involving any opioid and synthetic opioids other than methadone, including fentanyl, and increased for deaths involving psychostimulants with abuse potential and cocaine.
“Changes in rates varied by jurisdiction across drug type,” the authors write. “Rates for deaths involving synthetic opioids other than methadone decreased in 17 states and increased in 11 states.”
More information:
Matthew Garnett et al, Changes in Drug Overdose Mortality and Selected Drug Type by State in the United States, 2022 to 2023, Health E-Stats (2025). DOI: 10.15620/cdc/174578
Copyright © 2025 HealthDay. All rights reserved.
Citation:
2022 to 2023 saw decrease in rate of drug overdose deaths in United States: Report (2025, February 21)
retrieved 21 February 2025
from https://medicalxpress.com/news/2025-02-decrease-drug-overdose-deaths-states.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
